Cite
MLA Citation
Masahiro Nishikawa et al.. “CD44 expression in the tumor periphery predicts the responsiveness to bevacizumab in the treatment of recurrent glioblastoma.” Cancer medicine, vol. 10, 2021, pp. 2013–2025. http://access.bl.uk/ark:/81055/vdc_100123971637.0x000007